A Single Center, Open Label Pilot Study to Assess the Feasibility and Safety of Lumitrace Injection for Intraoperative Ureter Visualization Comparing White Light (WL) Fluorescence (BLUE) in Participants Undergoing Minimally Invasive Abdominopelvic Surgeries

The goal of this clinical trial is to learn if Lumitrace and the KARL STORZ POWER LED BLUE System can be used for anatomic visualization of the ureters in participants undergoing laparoscopic abdominopelvic surgery.
The main questions it aims to answer are:
* To evaluate the feasibility and clinical utility of Lumitrace to provide ureter visualization when used in tandem with the KARL STORZ POWER LED BLUE System during laparoscopic abdominopelvic surgery
* To evaluate the safety and tolerability of a single intravenous dose of Lumitrace in participants undergoing laparoscopic abdominopelvic surgery
Participants will participate in a Screening visit that will take place within 28 days of the scheduled administration of Lumitrace.
Up to 10 participants will be enrolled and will receive a single intravenous 130 mg dose of Lumitrace. Within 30 minutes of injection, the ureter visualization will be captured by the KARL STORZ POWER LED BLUE System using white light and fluorescence and the surgeon will rate ureter visualization for each illumination mode based on qualitative Likert Scales.
A safety follow-up visit will occur within 14 ±7 days of Lumitrace administration.

Start Date30 Jan 2026

Sponsor / Collaborator

MediBeacon, Inc.

NCT04008121

/ RecruitingEarly Phase 1

A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.

Start Date06 Nov 2025

Sponsor / Collaborator

MediBeacon, Inc.

NCT05777174

/ CompletedPhase 3

An Open Label, Multi-Center, Safety and Pharmacokinetic Bridging Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring in Normal and Renal Compromised Subjects for the Evaluation of Kidney Function

The goal of this clinical trial was to compare transdermal glomerular filtration rate (tGFR) to plasma-derived indexed GFR (nGFR) using MB-102 (relmapirazin) as the fluorescent compound. Adults with kidney function ranging from estimated glomerular filtration rate (eGFR) <120 to >15 mL/min/1.73 m2 and spanning the entire range of human skin colors as defined by the Fitzpatrick Skin Scale (FSS) were included in the study.
The main questions that the study aimed to answer were:
* To establish that the MB-102 transdermal fluorescence assessed GFR using the MediBeacon Transdermal GFR System with the TGFR reusable sensor with disposable adhesive ring was comparable to the measured MB-102 plasma GFR.
* To evaluate the safety and effectiveness of the MediBeacon Transdermal GFR System and the TGFR reusable sensor with disposable adhesive ring for the non-invasive transdermal fluorescence detection of MB-102 in participants
On dosing day, participants had the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon Transdermal GFR System initiated to collect background fluorescence. When this was completed, participants then received a single dose of MB-102. Blood samples were collected and fluorescent measurements were taken over a 12- or 24-hour (or longer) period, depending upon enrollment group. For those with significant renal compromise, fluorescent measurements were continued until the sensor no longer detected MB-102 in the body. Following completion of the treatment period, participants returned to the study center approximately 1 week later for a safety follow-up visit. Researchers compared the results to see if the transdermal GFR measurements were comparable to the measured plasma GFR.

Start Date20 Mar 2023

Sponsor / Collaborator

MediBeacon, Inc.

100 Clinical Results associated with Relmapirazin

100 Translational Medicine associated with Relmapirazin

100 Patents (Medical) associated with Relmapirazin

Literatures (Medical) associated with Relmapirazin

01 Apr 2026·Kidney International Reports

Accuracy of Point-of-Care Transdermal GFR Methodology

Article

Author: Dorshow, Richard B ; Friedemann, Jochen ; Trelford, Lester Paul ; Goldstein, Stuart L ; Riley, I Rochelle ; Harr, James ; Debreczeny, Martin P ; Vitale, Laura ; Ross-Jones, Jesse ; Johnson, James R

Introduction:

Chronic kidney disease (CKD) is typically staged using population-derived empirical equations to estimate glomerular filtration rate (GFR) based on serum creatinine and/or cystatin C. However, these estimated GFR (eGFR) equations can be inaccurate for an individual patient. Although plasma-derived GFR using an exogenous agent is the preferred methodology, the requirement for multiple blood samples and laboratory analysis limits its practical clinical utility. We have shown that the fluorescent molecule, relmapirazin, is an exogenous GFR tracer agent and its transdermal fluorescence detection at the point-of-care can assess a clinically relevant range of GFR across all human skin colors. In the current study, transdermal GFR (tGFR) was compared with the plasma-derived indexed GFR (nGFR) in a multicenter pivotal clinical study.

Methods:

We evaluated 182 participants with normal eGFR to CKD stage 4 across all 6 Fitzpatrick Skin Scale (FSS) types. A sensor attached to the chest contained a light emitting diode and photodetector for transdermal fluorescence detection following i.v. administration of relmapirazin. The primary end point was percentage of tGFR values within 30% of nGFR (P₃₀).

Results:

P₃₀ of 94% (95% confidence interval [CI]: 89%-97%) was obtained for the entire cohort. P₃₀ was 96% and 92% for participants with GFR > or < 60 ml/min per 1.73 m², respectively. P₃₀ of 96% was for participants with FSS I to III and 90% with IV to VI.

Conclusion:

The tGFR yielded a higher P₃₀ value than creatinine-based eGFR equations reported in the current literature. For the cohort subsets of CKD strata and FSS, all P₃₀ values observed were in the optimal range as established by the 2024 Kidney Disease: Improving Global Outcomes guideline.

02 Dec 2025·EXPERT OPINION ON BIOLOGICAL THERAPY

Current status and future potential of CD123-based targeted therapies for acute leukemia

Review

Author: Aldoss, Ibrahim ; Arslan, Shukaib ; Stein, Anthony ; Aribi, Ahmed

INTRODUCTION:

Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and blastic plasmacytoid dendritic cell neoplasm (BPDCN) are aggressive hematologic malignancies with poor outcomes, particularly in relapsed/refractory settings. CD123, the interleukin-3 receptor alpha chain, is highly expressed on leukemic blasts and leukemia stem cells, making it an attractive therapeutic target with limited expression on normal hematopoietic cells. CD123-directed therapies - including antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and CAR T-cell therapies - are under active investigation.

AREAS COVERED:

This review details the preclinical rationale, clinical development, efficacy, and toxicity of CD123-targeted therapies. It discusses completed and ongoing clinical trials for agents such as tagraxofusp, pivekimab sunirine, flotetuzumab, vibecotamab, and investigational CAR T-cell therapies (e.g. MB-102, UCART123v1.2). Toxicities, including myelosuppression, cytokine release syndrome (CRS), and hepatotoxicity - are characterized in detail, with attention to mitigation strategies. Future directions highlight combination regimens, switchable CAR designs, and biomarker-driven personalization.

EXPERT OPINION:

CD123-targeted therapy represents a promising yet challenging frontier in treating high-risk leukemias. While clinical activity has been demonstrated, especially in BPDCN, therapeutic durability and safety remain hurdles. Precision in antigen targeting, combination strategies, and toxicity management will be critical for successful integration of CD123-directed therapies into standard clinical practice.

01 Aug 2025·JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

GFR Measurement Using Transdermal Detection Methodology

Article

Author: Martin P. Debreczeny ; Richard B. Dorshow ; Stuart L. Goldstein

Key Points:

Transdermal fluorescence detection of GFR measurement at the point of care with the fluorescent GFR tracer agent relmapirazin was evaluated.Measurement over the entire range of clinically meaningful GFR and the entire range of human skin tones was demonstrated. A linear regression of transdermally derived GFR to plasma-derived GFR yielded an r2 of 0.90 and P30 of 91.9%.

Background:

The well-known accuracy limitations of eGFR currently used in clinical practice present barriers to optimal care for patients with, or at risk of, decreased kidney function. A point-of-care GFR measurement methodology has the potential to address these limitations. We prospectively assessed transdermal detection of the novel fluorescent GFR tracer agent relmapirazin in participants having normal or impaired kidney function across all human skin colors on the Fitzpatrick Skin Scale (FSS).

Methods:

A multicenter study comprising 74 participants with eGFR from normal to stage 4 CKD was performed. Forty-six participants were FSS types 1–3, and 28 were FSS types 4–6. A module containing a light-emitting diode and photodetector to activate and collect transdermal relmapirazin fluorescence was attached adhesively to the upper chest of each participant. Relmapirazin (1.5 mg/kg) was administered by intravenous push, and fluorescence emission was acquired for 12 hours. A two-compartment pharmacokinetic model fit the fluorescent intensity versus time data, and fluorescence clearance rate (FCR) was extracted from the second (terminal) compartment. Plasma relmapirazin concentrations were measured contemporaneously, and the corresponding plasma GFR for each participant was determined. Linear regression analysis was used to compare the FCR with the indexed plasma GFR.

Results:

Participant age range was 23–80 years, with 59% female. The two-compartment pharmacokinetic behavior was observed in the fluorescence intensity versus time data, and a FCR was successfully deduced for every participant completing the 12-hour study. The FCR versus indexed plasma GFR yielded an excellent correlation over the range of GFR measured and for all skin colors with a r2 of 0.90 (95% confidence interval, 0.85 to 0.94). No severe adverse events were reported.

Conclusions:

Point-of-care transdermal detection of the fluorescent GFR tracer agent relmapirazin was feasible in patients with normal to impaired kidney function and for a range of skin color types.

Clinical Trial registry name and registration number::

ClinicalTrials.gov, NCT02772276.

Podcast:

This article contains a podcast at https://dts.podtrac.com/redirect.mp3//www.asn-online.org/media/podcast/JASN/2025_12_10_KTS_December2025.mp3

News (Medical) associated with Relmapirazin

31 Mar 2026

·www.biospace.com

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

ST. LOUIS, March 31, 2026 (GLOBE NEWSWIRE) -- MediBeacon Inc. , a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced receipt of European Union (EU) CE Mark certification under the EU Medical Device Regulation (MDR) for its TGFR ™ Monitor and TGFR ™ Reusable Sensor. The certification confirms that the Monitor and Sensor have met the robust safety, quality, and performance standards required under the EU MDR 2017/745. “Obtaining the EU CE Mark is a significant milestone for MediBeacon,” said Steven Hanley, CEO and Co-Founder of MediBeacon. “As the TGFR ™ System enters the clinic in the U.S. and China, the CE Mark allows for the potential use of the transdermal technology in clinical trials that include European sites. The achievement also underscores our commitment to meeting the highest quality and safety standards.” MediBeacon received certification across two Class IIa devices, the TGFR Monitor and TGFR Reusable Sensor. The two, coupled with the Lumitrace ® (relmapirazin) injection and the CE marked TGFR ™ Disposable Ring, comprise the TGFR System, which enables the assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The result is a transdermal assessment of Glomerular Filtration Rate or kidney function (tGFR). Lumitrace (relmapirazin) injection is approved in the U.S. and China. Submission of Lumitrace (relmapirazin) injection to the EU regulatory authorities is pending. “An accurate, clinically practical, point of care method to assess kidney function could be revolutionary in the development and implementation of future strategies designed to help patients who are at risk of renal complications,” said Dr. Lui Forni, a lead intensive care medicine physician at the Royal Surrey County Hospital NHS Foundation Trust and a global leader in critical care nephrology. “I look forward to including transdermal GFR in my clinical research in Europe later this year.” Media and Investor Contact Caylene Parrish investors@medibeacon.com About MediBeacon Inc . MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection. MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function. MediBeacon owns over 55 granted U.S. patents and over 250 granted patents worldwide that provide extensive coverage of the MediBeacon ® TGFR™ System, including Lumitrace ® injection, the sensor and algorithms, as well as other strategic uses of its proprietary pyrazine platform and sensor technology. The TGFR System including Lumitrace is approved for human use by the U.S. FDA and the China NMPA. In addition, the TGFR ™ Monitor, TGFR ™ Reusable Sensor, and TGFR ™ Disposable Ring, have received the EU MDR CE Mark. Potential technology applications in gastroenterology, ophthalmology, and surgery are in various stages of clinical development. MediBeacon is based in St. Louis, Missouri, with additional operations in Mannheim, Germany. For more information, please visit: . About Lumitrace ® (relmapirazin) injection Relmapirazin is a non-radioactive, non-iodinated, pyrazine-based compound, which has been engineered to be inert, highly fluorescent, and have the clearance properties of a GFR tracer agent in the body. The unique photophysical characteristics of Lumitrace have been designed to enable the collection of fluorescence data via a photodetector sensor placed on the skin. Data collected by the sensor measures the change in the intensity of Lumitrace fluorescence over time and is converted into a transdermal GFR (tGFR) by proprietary algorithms. In a phase 2 investigational study, mGFR deduced from Lumitrace matched that of mGFR deduced from iohexol over a range of GFR values. See the peer reviewed article published in the October 2024 issue of Kidney International by Dorshow et al. 1 About MediBeacon ® TGFR™ System The MediBeacon ® TGFR ™ System is comprised of the TGFR ™ Reusable Sensor, TGFR ™ Monitor, TGFR ™ Disposable Ring, and Lumitrace ® (relmapirazin) injection, which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The system records Lumitrace fluorescence intensity transdermally as a function of time via a sensor placed on the skin. The TGFR Reusable Sensor records 2.5 fluorescent readings per second and the TGFR Monitor displays the average session tGFR reading at the point of care. FOR IMPORTANT SAFETY INFORMATION FOR THE TGFR SYSTEM (U.S. FDA) see ifu.medibeacon.com . ____________________________________ 1 Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102), Kidney International, Volume 106, Issue 4, P679-687, October 2024, DOI: 10.1016/j.kint.2024.06.012

Drug ApprovalClinical ResultPhase 2

11 Feb 2026

·www.biospace.com

Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephrology (JASN)

MediBeacon ® Transdermal GFR System is a first-in-kind product for point of care kidney function assessment Centers of Excellence commercialization in select academic medical centers began in January 2026 ST. LOUIS, Feb. 10, 2026 (GLOBE NEWSWIRE) -- MediBeacon Inc. , a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced that the peer-reviewed transdermal GFR measurement article published in the Journal of the American Society of Nephrology (JASN) has been recognized as one of five 2025 Editor’s Choice articles. 1 The JASN editorial team selects five top articles each year which exemplify the highest potential to inform future research, change clinical practice, and/or guide public policy, particularly in the United States. The article was featured on the cover of the Journal of the American Society of Nephrology (JASN) in August 2025. 2 The TGFR ™ System is comprised of Lumitrace ® (relmapirazin) injection, the TGFR ™ Monitor and TGFR ™ Reusable Sensor and enables the assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The result is a transdermal assessment of Glomerular Filtration Rate or kidney function (tGFR). “There is an acute need for improved GFR assessment at the point of care. Assessing the impact of physiologic changes or diseases on GFR in is of high potential clinical value. The limitations of estimated GFR (eGFR) are well known and existing measured GFR (mGFR) methodologies are not well suited to general clinical practice,” said Dr. Steve Miller, Chief Medical Officer for MediBeacon. “Many of the top institutions view transdermal GFR (tGFR) as a potential clinical practice game changer targeting a new standard of care for patients in numerous cases where the understanding of kidney function is fundamental.” “We are excited about this recognition by American Society of Nephrology,” said Steven Hanley, CEO and Co-Founder of MediBeacon. “Our deployment of the TGFR System across key centers of excellence, initially targets use in heart failure monitoring, transplant evaluation and oncology drug dosing. Our collaboration with the top hospitals globally demonstrates this focus to strategically drive early commercial adoption of our technology where it can rapidly be demonstrated to have high clinical value.” Media and Investor Contact Ji-Yon Yi investors@medibeacon.com About MediBeacon Inc . MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection. MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function. MediBeacon owns over 55 granted U.S. patents and over 250 granted patents worldwide that provide extensive coverage of the MediBeacon ® TGFR™ System, including Lumitrace ® injection, the sensor and algorithms, as well as other strategic uses of its proprietary pyrazine platform and sensor technology. The TGFR System is approved for human use. Potential technology applications in gastroenterology, ophthalmology and surgery are in various stages of clinical development. MediBeacon is based in St. Louis, Missouri, with additional operations in Mannheim, Germany. For more information, please visit: . About Lumitrace ® (relmapirazin) injection Relmapirazin is a non-radioactive, non-iodinated pyrazine-based compound, which has been engineered to be inert, highly fluorescent, and have the clearance properties of a GFR tracer agent in the body. The unique photophysical characteristics of Lumitrace have been designed to enable the collection of fluorescence data via a photodetector sensor placed on the skin. Data collected by the sensor measures the change in the intensity of Lumitrace fluorescence over time and is converted into a transdermal GFR (tGFR) by proprietary algorithms. In a phase 2 investigational study mGFR deduced from Lumitrace matched that of mGFR deduced from iohexol over a range of GFR values. See the peer reviewed article published in the October 2024 issue of Kidney International by Dorshow et al. 3 About MediBeacon ® TGFR™ System The MediBeacon ® TGFR ™ System is comprised of the TGFR ™ Reusable Sensor, TGFR ™ Monitor, TGFR ™ Disposable Ring, and Lumitrace ® (relmapirazin) injection, which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The system records Lumitrace fluorescence intensity transdermally as a function of time via a sensor placed on the skin. The TGFR Reusable Sensor records 2.5 fluorescent readings per second and the TGFR Monitor will display the average session tGFR reading at the point of care. FOR IMPORTANT SAFETY INFORMATION FOR THE TGFR SYSTEM (U.S. FDA) see ifu.medibeacon.com . 1 2 Glomerular Filtrate Rate Measurement Utilizing Transdermal Detection Methodology; Dorshow, Richard B., Debreczeny, Martin P.; Goldstein, Stuart L.; Journal of the American Society of Nephrology, 36(8):p 1592-1602, August 2025. DOI: 10.1681/ASN 0000000639 3 Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102), Kidney International, Volume 106, Issue 4, P679-687, October 2024, DOI: 10.1016/j.kint.2024.06.012

Clinical ResultPhase 2

30 Oct 2025

·www.globenewswire.com

MediBeacon to Present at the Upcoming American Society of Nephrology (ASN) Kidney Week 2025

ST. LOUIS, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced that data from the Company’s transdermal GFR technology has been accepted for an oral presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, November 5-9, 2025. The presentation titled, “A clinical study evaluating accuracy of the transdermal glomerular filtration rate methodology in CKD patients,” will be given at 5:40 PM CST on November 7, 2025 by Stuart L. Goldstein, M.D., Director of the Center for Acute Care Nephrology at Cincinnati Children’s Hospital Medical Center. “We look forward to presenting data from a growing body of evidence that supports transdermal GFR use in kidney function assessment,” said Dr. Goldstein. “By continuing to examine the accuracy of transdermal GFR, our focus is to pave the way for better care of kidney patients.” Key clinical study points: Transdermal fluorescence detection of relmapirazin to assess GFR across all human skin colors and CKD stages 1-4A statistical comparison of transdermal GFR (tGFR) to plasma-derived indexed GFRThe tGFR P30 value met the Kidney Disease Improving Global Outcomes (KDIGO) guidelines for optimal P30 range (>90%)FDA approval of the Transdermal GFR System resulted from this study led by Dr. Richard B. Dorshow, Chief Scientific Officer at MediBeacon and first author of the presentation MediBeacon’s CEO, Steven Hanley, will present at the upcoming Stifel Healthcare Conference in New York on Tuesday, Nov. 11, 2025 at 5:40 AM PST / 8:40 AM EST. Media and Investor ContactCarrie Mendivil / Ji-Yon Yiinvestors@medibeacon.com About Lumitrace® (relmapirazin) injectionRelmapirazin is a non-radioactive, non-iodinated pyrazine-based compound, which has been engineered to be inert, highly fluorescent, and have the clearance properties of a GFR tracer agent in the body. The unique photophysical characteristics of Lumitrace have been designed to enable the collection of fluorescence data via a photodetector sensor placed on the skin. Data collected by the sensor measures the change in the intensity of Lumitrace fluorescence over time and is converted into a transdermal GFR (tGFR) by proprietary algorithms. In a phase 2 investigational study mGFR deduced from Lumitrace matched that of mGFR deduced from iohexol over a range of GFR values. See the peer reviewed article published in the October 2024 issue of Kidney International by Dorshow et al.1 About MediBeacon® Transdermal GFR System (TGFR) The MediBeacon TGFR is comprised of the MediBeacon TGFR Sensor, MediBeacon TGFR Monitor, and Lumitrace® (relmapirazin), which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The system records Lumitrace fluorescence intensity transdermally as a function of time via a sensor placed on the skin. The TGFR Sensor records 2.5 fluorescent readings per second and the TGFR Monitor will display the average session tGFR reading at the patient’s bedside or in the outpatient setting. FOR IMPORTANT SAFETY INFORMATION FOR TGFR (U.S. FDA) see ifu.medibeacon.com. About MediBeacon Inc.MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection. MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function. MediBeacon owns over 60 granted U.S. patents and over 245 granted patents worldwide that provide extensive coverage of the MediBeacon® TGFR, including Lumitrace® injection, the sensor and algorithms, as well as other strategic uses of its proprietary pyrazine platform and sensor technology. The TGFR is approved for human use. Potential technology applications in gastroenterology, ophthalmology and surgery are in various stages of clinical development. MediBeacon is based in St. Louis, Missouri, with additional operations in Mannheim, Germany. For more information, please visit: www.medibeacon.com. 1 Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102), Kidney International, Volume 106, Issue 4, P679-687, October 2024, DOI: 10.1016/j.kint.2024.06.012

Clinical Result

100 Deals associated with Relmapirazin

External Link

KEGG	Wiki	ATC	Drug Bank
D11637	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glomerular disease	United States	MediBeacon, Inc.	17 Jan 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 3	United States	MediBeacon, Inc.	14 Jun 2022
Chronic Kidney Diseases	Phase 3	China	MediBeacon, Inc.	14 Jun 2022
Renal Insufficiency	Phase 3	United States	Curia Global Holdings Ltd.	14 Jun 2022
Renal Insufficiency	Phase 3	United States	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	14 Jun 2022
Acute Kidney Injury	Phase 2	United States	MediBeacon, Inc.	11 May 2016
Ureteral Diseases	Phase 1	United States	MediBeacon, Inc.	30 Jan 2026
Diabetic Retinopathy	Phase 1	United States	MediBeacon, Inc.	06 Nov 2025
Dystrophy, Macular	Phase 1	United States	MediBeacon, Inc.	06 Nov 2025
Retinal Vein Occlusion	Phase 1	United States	MediBeacon, Inc.	06 Nov 2025
Crohn Disease	Phase 1	United States	MediBeacon, Inc.	27 Oct 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05777174 (CTgov)	Phase 3	Renal Insufficiency	149	MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)+MB-102 (Participants With eGFR ≥ 70 mL/Min/1.73 m^2)	vxcmjnwwtu = vbystaxxcu mgyaililxa (jxyfpixdbn, rgvncpwixu - rollxbyhwo) View more	-	28 Mar 2025
				MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)+MB-102 (Participants With eGFR < 70 mL/Min/1.73 m^2)	vxcmjnwwtu = chmxderoii mgyaililxa (jxyfpixdbn, qafweywohr - sunskdfqwp) View more
NCT05425719 (CTgov)	Phase 3	Chronic Kidney Diseases	249	MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)+MB-102 (eGFR ≥ 70 mL/Min/1.73 m^2)	seglehnflp = uzgrsvctrt fhftgvxdsk (cuxxtjdnpx, senjooxbpa - sorkvryxth) View more	-	18 Apr 2024
				MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)+MB-102 (eGFR < 70 mL/Min/1.73 m^2)	seglehnflp = ewaiduddjb fhftgvxdsk (cuxxtjdnpx, dgljdzcflb - kdmkxkwkal) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis